May 29, 2024 03:17 PM EDT
Pharma
FDA+

Lil­ly's Retev­mo lands new ac­cel­er­at­ed ap­proval for pe­di­atric can­cers

Zachary Brennan

Senior Editor

The FDA on Wednes­day grant­ed an­oth­er ac­cel­er­at­ed ap­proval to Eli Lil­ly’s can­cer drug Retev­mo, this time for pe­di­atric pa­tients age 2 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times